65,437 trials
Metastatic Colorectal Adenocarcinoma
Primary: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B — 39.3 Percentage of Participants
Any Solid Malignancies of Any Tissue Origin (Except for Small Cell Lung Cancer) Involving the Upper Abdomen and Thorax
Primary: Percentage of Scheduled Treatment Fractions Delivered Successfully Using the Surface Guidance System — 100 percentage of treatment fractions
Vaccine Refusal
Primary: Change in Knowledge Related to Childhood Vaccinations as Measured by Study Specific Questionnaire — 1.27 score on a scale
HIV Infection · Drug Use
Primary: Undetectable HIV Viral Load at 12 Months — 46.9; 22.7 percentage of participants
Advanced Hepatocellular Carcinoma
Primary: 24-Week Progression-Free Survival Rate (PFSR) — 59.8; 16.7 percentage of participants
Overweight · Obesity
Primary: Change in Body Mass Index (BMI) (Percentage [%]) — -16.2; -0.1 Percentage change of BMI — p=<.0001
Prostate Cancer
Primary: Percentage of Participants With Biochemical Failure (Primary Endpoint of Revised Protocol) — 17.3; 12.8 percentage of participants — p=0.55
Solid Tumors
Primary: Number of Participants With Overall Response Rate (ORR) — 2; 6 Participants
Lower Face Folds and Lines
Primary: Number of Participants (Responders) With Aesthetic Improvement by the Treating Investigator Assessment Using Global Aesthetic Improvement Scale (GAIS) at Week 3 — 18…
Chordoma
Primary: Objective Response Rate (ORR) — 7.7 percentage of subjects with OR
Debility Due to Disease
Primary: Number of Participants Who Experience an Adverse Event During Time of Treatment — 5 Participants
Psoriasis
Primary: Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy) — 3; 1 Participants — p=0.43
Lung Diseases
Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants
Exposure to Herbicides
Primary: Specific Gravity-adjusted Urinary Glyphosate Concentrations During Conventional and Organic Diet — 0.19; 0.17; 0.18; 0.14 ug/L — p=0.17
HIV · Human Immunodeficiency Virus
Primary: Time to Virologic Failure After Initiating PRO 140 Monotherapy. — 70.71 days — p=<0.0001